Table 1 Summary of the therapeutic regimens used for the treatment of dermatologic manifestations of systemic AL amyloidosis, by the date of publication

1. Beachman et al [5]

Diffuse Bullous Amyloidosis of skin

Upper Extremities

(Am Acad Dermatol)

1980

Melphalan + Prednisone

No Clinical CR, 9 mo

2. Ruzicka et al [6]

Bullous amyloidosis

Generalized Skin

(Brit J Dermatol)

1985

Dapson/Prednisone CR

3. Bieber et al [13]

Hemorrhagic Bullous Amyloidosis

Multiple skin folds

(Arc Dermatol)

1988

Melphalane + Prednisone

Lesions healed with milia

4. Johnson et al [2]

Non-Hemorrhagic Bullous Amyloidosis

Trunk & Proximal Extremities

(CUTIS)

1989

Prednisone + Azathioprine

Treatment failed

5. Pramatarov et al [14]

Multiple Hemorrhagic skin Lesions with systemic Amyloidosis

Multiple skin lesions

(Intern J Dermatol)

1990

Cochicine + DMSO

Partial response

6. Robert et al [3]

Bullous Amyloidosis of skin, 3 cases

Multiple skin

(Medicine)

1993

Alkylating Agents

Poor Response

7. Grundmann et al [7]

Extensive Hemorrhagic Bollous AA-Amyloidosis

Generalized Skin

(Eur J. Med)

2000

Dexamethasone Stabilized after 3 cycles

8. Ochiai et al [15]

Bullous Pemphigoid Amyloidosis of Hands Systemic AA-amyloidosis

Hands & Feet

(J Cutan Pathol)

2001

CHOP

---

9. Comenzo et al [16]

Review Article Systemic Amyloidosis

---

(Blood)

2002

Melphalane + ASCT

100-day mortality of 21-39 %

10. Gertz et al [17]

Primary Systemic Amyloidosis

Systemic/Skin

(Am J Medicine)

2002

ASCT

Treatment-related Mortality of 14 %

11. Goodman et al [18]

AL Amyloidosis

Systemic/skin

(Brit J Haem)

2006

HD chemotherapy + 100-day mortality ASCT

23 %

12. Giovanni et al [12]

Advanced AL

Systemic/Skin Amyloidosis

(52nd ASH Meeting)

2010

Lenalidomide + Dexamethasone Mortality 13 %

No CR, PHR 41 %,